{
     "PMID": "8314196",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "19940318",
     "LR": "20151119",
     "IS": "0767-3981 (Print) 0767-3981 (Linking)",
     "VI": "7",
     "IP": "9",
     "DP": "1993",
     "TI": "Biochemical and electrophysiological properties of SR 57746A, a new, potent 5-HT1A receptor agonist.",
     "PG": "487-97",
     "AB": "SR 57746A (1-[2-(naphth-2-yl) ethyl]-4-(3-trifluoromethylphenyl)-1, 2, 5, 6 tetra-hydropyridine hydrochloride) binds competitively, and with high affinity (Ki = 2.0 +/- 0.7 nM) to 5-HT1A receptors from rat hippocampus in vitro, but has much less affinity for other 5-HT receptor subtypes (IC50 > 650 nM). SR 57746A produces a concentration-dependent inhibition of forskolin-stimulated adenylate cyclase activity in rat hippocampal homogenates, with a maximal effect identical to that of 8-OH-DPAT, suggesting that SR 57746A behaves as a full agonist in this experimental model. SR 57746A potently displaces [3H]8-OH-DPAT binding to rat hippocampal membranes ex vivo, with an ID50 of 11.1 mg/kg po, 30 min after administration, and 2.8 mg/kg po, 2 h after administration. This effect of SR 57746A is long-lasting (at least 24 hours at 10 mg/kg po). SR 57746A does not modify the levels of 5-HT or DA in various brain areas, but decreases the concentrations of 5-HIAA, and increases those of DOPAC, HVA and 3-MT. Following i.v. administration, SR 57746A (0.095 to 0.25 mg/kg) inhibits the spontaneous firing of dorsal raphe neurones, but does not modify the activity of DA neurones in the substantia nigra or ventral tegmental area. Thus, SR 57746A is a potent, selective and full agonist at 5-HT1A receptors in vitro and vivo.",
     "FAU": [
          "Bachy, A",
          "Steinberg, R",
          "Santucci, V",
          "Fournier, M",
          "Landi, M",
          "Hamon, M",
          "Manara, L",
          "Keane, P E",
          "Soubrie, P",
          "Le Fur, G"
     ],
     "AU": [
          "Bachy A",
          "Steinberg R",
          "Santucci V",
          "Fournier M",
          "Landi M",
          "Hamon M",
          "Manara L",
          "Keane PE",
          "Soubrie P",
          "Le Fur G"
     ],
     "AD": "Sanofi Recherche, Toulouse, France.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Comparative Study",
          "Journal Article"
     ],
     "PL": "England",
     "TA": "Fundam Clin Pharmacol",
     "JT": "Fundamental & clinical pharmacology",
     "JID": "8710411",
     "RN": [
          "0 (Amines)",
          "0 (Naphthalenes)",
          "0 (Pyridines)",
          "0 (Receptors, Serotonin)",
          "0 (Serotonin Receptor Agonists)",
          "10028-17-8 (Tritium)",
          "78950-78-4 (8-Hydroxy-2-(di-n-propylamino)tetralin)",
          "EC 4.6.1.1 (Adenylyl Cyclases)",
          "V8QL94KNQO (xaliproden)"
     ],
     "SB": "IM",
     "MH": [
          "8-Hydroxy-2-(di-n-propylamino)tetralin/metabolism",
          "Adenylyl Cyclases/metabolism",
          "Amines/metabolism",
          "Animals",
          "Electrophysiology",
          "Hippocampus/drug effects/enzymology/metabolism",
          "Male",
          "Membranes/enzymology",
          "Naphthalenes/metabolism/*pharmacology",
          "Neurons/drug effects/physiology",
          "Pyridines/metabolism/*pharmacology",
          "Raphe Nuclei/drug effects/physiology",
          "Rats",
          "Rats, Sprague-Dawley",
          "Receptors, Serotonin/metabolism",
          "Serotonin Receptor Agonists/metabolism/*pharmacology",
          "Substantia Nigra/drug effects/physiology",
          "Tritium",
          "Ventral Tegmental Area/drug effects/physiology"
     ],
     "EDAT": "1993/01/01 00:00",
     "MHDA": "1993/01/01 00:01",
     "CRDT": [
          "1993/01/01 00:00"
     ],
     "PHST": [
          "1993/01/01 00:00 [pubmed]",
          "1993/01/01 00:01 [medline]",
          "1993/01/01 00:00 [entrez]"
     ],
     "PST": "ppublish",
     "SO": "Fundam Clin Pharmacol. 1993;7(9):487-97.",
     "term": "hippocampus"
}